Tehran University of Medical Sciences Journal of Pharmacoeconomics and Pharmaceutical Management 2383-4498 4 3/4 2018 11 14 53 57 Afshin Shiva Department Clinical Pharmacy, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran. Milad Azemoodeh Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran. 2019 04 10 Background: The present study was conducted to evaluate the use of vancomycin according to the Healthcare Infection Control Practices Advisory Committee guidelines in the Imam Khomeini hospital of Urmia. Methods: This retrospective study was conducted in Urmia Imam Khomeini Hospital (intensive care unit, surgery, internal medicine, and dialysis wards). In the retrospective phase, the demographic and clinical data related to all patients who were treated with vancomycin in April, May, and June 2015 were collected according to a HICPAC-based questionnaire. The level of compliance of vancomycin with the recommendations mentioned was determined. Non-compliance with the instructions was identified as the goal of the next interventions. Results: The results of our study showed that the highest starting doses were among the patients with pneumonia. We did not measure the serum level of vancomycin in none of the patients studied. The duration of treatment for patients was 4.45±4.91 days. Also, our results showed that 68.5% of patients had no antibiogram before the treatment. Conclusion: The obtained findings showed that the necessity of an antibiogram and patient’s weight measurement and avoiding the simultaneous use of broad-spectrum antibiotics and measuring the serum level of vancomycin in order to promote patients’ treatment and promote the use of broad-spectrum antibiotics Vancomycin should be taken into consideration. https://jppm.tums.ac.ir/index.php/jppm/article/view/113 https://jppm.tums.ac.ir/index.php/jppm/article/download/113/59